COVID-19 has disrupted the UK’s plans to negotiate a favorable-terms exit from the EU by the end of 2020, but the government is sticking to its official line of no transition extension beyond 31 December. That clarity of thought does not apply equally to the shape of UK stand-alone medtech regulation, work on which restarts at UK parliamentary level on 11 June. That is when the proposed UK Medicines and Medical Devices (MMD) Bill potentially reaches the report stage in parliament.
There has been little movement on the MMD in recent weeks, said Melissa Barnet, of political communications company PB Consulting, ahead of the 27 May parliamentary enquiry in the progress...
